Eli Lilly & Company: Oral Obesity Prescription Tracker
Report Coverage
- Broker
- JPMorgan
- Region
- United States
- Report Type
- Company Report
- Primary Focus
- Eli Lilly & Company
Full Report Document Access
This page is a research report summary and access guidance page. If you are searching for JPMorgan Eli Lilly & Company research report PDF or the full report document, use the summary, coverage fields and related links to confirm relevance before requesting VIP access. Full PDF report access is available to VIP members after request confirmation; the PDF is not publicly displayed on this page.
Report Summary
Chris Schott, CFA AC North America Equity Research (1-212) 622-5676 19 June 2026 JPMORGAN [email protected] the company pages of our client website, http://www.jpmorganmarkets.com . This report also sets out within it the material underlying History of Investment Recommendations: A history of J.P. Morgan investment recommendations disseminated during the preceding 12 months can be accessed on the Research & Commentary page of http://www.jpmorganmarkets.com where you can also search by analyst name, sector or financial instrument. Analysts' Compensation:The research analysts responsible for the preparation of this report receive compensation based u
Key Takeaways
- Weekly TRx for the obesity market grew ~79% / ~499k TRx YoY looking
- Zepbound TRx were up ~59% YoY, translating to +240k weekly TRx for
- Looking at low-dose NRx of Zepbound (as a proxy for new patient starts),
- Please note that there has been a data capture issue (starting the week
- The Oral Wegovy launch is off to a solid start and appears market
- Oral Wegovy has launched well with ~161.5k TRx / 132.9k NRx as of the
Why This Report Matters
JPMorgan's 11-page analysis on "Eli Lilly & Company: Oral Obesity Prescription Tracker" provides institutional-grade insights for investors and professionals seeking to understand current market dynamics and investment implications in this space.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the JPMorgan Eli Lilly & Company report. It helps users review Eli Lilly & Company: Oral Obesity Prescription Tracker coverage, key takeaways, and related broker or sector research paths across Lilly, Company:, Oral; North America Equity Research, June.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.